Last reviewed · How we verify
Autologous MUC1-activated T-cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Autologous MUC1-activated T-cells (Autologous MUC1-activated T-cells) — Mayo Clinic.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Autologous MUC1-activated T-cells TARGET | Autologous MUC1-activated T-cells | Mayo Clinic | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Autologous MUC1-activated T-cells CI watch — RSS
- Autologous MUC1-activated T-cells CI watch — Atom
- Autologous MUC1-activated T-cells CI watch — JSON
- Autologous MUC1-activated T-cells alone — RSS
Cite this brief
Drug Landscape (2026). Autologous MUC1-activated T-cells — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-muc1-activated-t-cells. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab